[1] Olar A, Aldape K D. Using the molecular classification of glioblastoma to in form personalized treatment[J]. J Pathol, 2013, 232(2):165-177. [2] Seyfried T N, Shelton L M, Mukherjee P. Does the existing standard of care increase glioblastoma energy metabolism?[J]. Lancet Oncol, 2010, 11(9):809-811. [3] Liberti M V, Locasale J W. Correction to:'the warburg effect:how does it benefit cancer cells?[J]. Trends Biochem Sci, 2016, 41(3):211-218. [4] Caraballo R H, Flesler S, Armeno M, et al. Ketogenic diet in pediatric patients with refractory focal status epilepticus[J]. Epilepsy Res, 2014, 108(10):1912-1916. [5] Youm Y H, Nguyen K Y, Grant R W, et al. Ketone body β-hydroxybutyrate blocks the NLRP3 inflammasome-mediated inflammatory disease[J]. Nat Med, 2015, 21(3):263-269. [6] Lussier D M, Woolf E C, Johnson J L, et al. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet[J]. BMC Cancer, 2016, 16(1):310. [7] Nebeling L C, Miraldi F, Shurin S B, et al. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients:two case reports[J]. J Am Coll Nutr, 1995, 14(2):202-208. [8] Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy with a restricted ketogenic diet:case report[J]. Nutr Metab (Lond),2010,7:33. [9] Abdelwahab M G, Fenton K E, Preul M C, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma[J]. PLoS One, 2012, 7(5):e36197. [10] Lavanya B A, Caroline D R. β-Hydroxybutyrate in the brain:one molecule, multiple mechanisms[J]. Neurochem Res, 2017, 42(1):1-15. [11] Woolf E C, Syed N, Scheck A C. Tumor metabolism, the ketogenic diet and β-hydroxybutyrate:novel approaches to adjuvant brain tumor therapy[J]. Front Mol Neurosci, 2016, 9:122. [12] Newman J C, Verdin E. β-hydroxybutyrate:much more than a metabolite[J]. Diabetes Res Clin Pract, 2014, 106(2):173-181. [13] Ganapathykanniappan S, Geschwind J F. Tumor glycolysis as a target for cancer therapy:progress and prospects[J]. Mol Cancer, 2013, 12(1):152. [14] Newman J C, Verdin E. Ketone bodies as signaling metabolites[J]. Trends Endocrinol Metab, 2014, 25(1):42-52. [15] Shukla S K, Gebregiworgis T, Purohit V, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia[J]. Cancer Metab, 2014, 2(1):18-18. [16] Dang C V, Le A, Ping G. MYC-induced cancer cell energy metabolism and therapeutic opportunities[J]. Clin Cancer Res, 2009, 15(21):6479-6483. [17] Dejure F R, Eilers M. MYC and tumor metabolism:chicken and egg[J]. EMBO J, 2017, 36(23):3409. [18] 黄婷, 李军,卢驰,等.脑胶质瘤组织RRM1表达临床意义[J].中华肿瘤防治杂志,2018,25(6):394-401. |